Background: F-18 Flurpiridaz is a newly FDA-approved tracer for PET MPI with a long half-life and improved physical characteristics. However, its long half-life leads to residual rest activity. Prior trials used 30 to 60 minutes delays between rest and stress injections and proposed stress-to-rest dose ratios of 1:2 to 1:3 to mitigate the potential impact of residual rest counts on the stress myocardial perfusion images. Objective: To evaluate the effect of stress-to-rest dose ratio and time interval between injections on residual activity. Methods: We analyzed consecutive 115 patients who underwent PET MPI with F-18 Flurpiridaz. Relative Residual activity was calculated as the ratio of tissue activity concentration (kBq/mL) in the first stress frame to that in the stress tissue phase. Linear regression was used to assess the association of dose ratio and injection time interval with global residual activity. The optimal dose ratio cutoff was identified. Mixed-effects models with interaction terms were used to assess whether the effect varied across vascular territories. Results: A total of 115 patients underwent PET MPI. Results showed that increasing the stress-to-rest dose ratio was significantly associated with lower relative residual activity (β = -3.41; 95% CI: -4.72; -2.11 per 1-unit increase), while the time interval between injections showed no significant association (β =0.03 95% CI: -0.12; 0.17 per 1-minute increase). The optimal cutoff dose ratio to achieve relative residual activity <20% ranged between 3.2 and 4.3. Conclusion: Increasing the stress-to-rest dose ratio between 3.2 and 4.3, effectively reduces residual activity to <20% of the stress dose across all time intervals, thereby enabling back-to-back imaging and improving protocol efficiency.

Dr. Al-Mallah receives research support from Siemens and GE Healthcare. He is also a consultant to GE Healthcare and Jubilant.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Institutional Review Board at Houston Methodist Hospital.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors